View Financial HealthPercheron Therapeutics 배당 및 자사주 매입배당 기준 점검 0/6Percheron Therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률0%자사주 매입 수익률총 주주 수익률0%미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 16Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 434,975,053 Price\Range: AUD 0.005 Security Features: Attached Options Transaction Features: Rights Offering공시 • Aug 28Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025.공시 • Nov 26Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing공시 • Nov 15Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,160,916 Price\Range: AUD 0.008공시 • Oct 23Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: AUD 0.08공시 • Oct 18Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing공시 • Oct 17Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023, at 14:00 AUS Eastern Standard Time. Location: Minter Ellison, Collins Arch Level 20 447 Collins Street Melbourne VIC 3000 Melbourne Australia Agenda: To receive and consider the Annual Financial Report of the Company for the year ended 30 June 2023 (2023 Annual Report), comprising the Financial Report, the Directors' Report, and the Auditor's Report; to consider Non-Binding Resolution to Adopt the 2023 Remuneration Report; to consider Re-Election of Director Dr. Charmaine Gittleson; to consider Ratification of Prior Issue of Shares to Institutional Investors; to consider Approval for issue of Options to Dr. James Garner; to consider Approval of Employee Share Option Plan; to consider Approval for issue of Options to Dr. Charmaine Gittleson; to consider Approval of change of Company name and modification of Constitution; and to consider Approval of 10% Placement Facility.공시 • Jun 29Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UKAntisense Therapeutics Limited announced that it has received both regulatory authority and ethics committee approval to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD) in the United Kingdom (UK). Following these approvals, requisite contracts are anticipated to be finalised for initiation of trial sites, expected during third quarter current year 2023.공시 • May 08+ 1 more updateAntisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023The Board of Directors of Antisense Therapeutics Limited announced the appointment of Dr James Garner MBBS MBA as Chief Executive Officer (CEO). Dr Garner will assume the roles as of 07 August 2023. This appointment follows the previously announced retirement, on 15 November 2022, of Mr. Mark Diamond from the roles of MD and CEO, with Mark's last working day 12 May 2023. To ensure continuity and leadership, Dr Charmaine Gittleson will assume the role of Executive Chairman, with immediate effect, until James is settled in his CEO and MD duties. James brings broad experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector. His previous responsibilities have included leading phase I-IV clinical trials, product registration, reimbursement, and business development. He possesses strong executive leadership and management skills that have seen him achieve outstanding results over a twenty-year career in the Pharmaceutical/Biotechnology industry including roles with Biogen, Progen Pharmaceuticals, Quintiles (an international clinical research organisation) and as Head of the Unit Development Office, AP R&D with Sanofi in Singapore. Most recently James has served as CEO of Kazia Therapeutics Limited.공시 • Feb 15Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device AgencyAntisense Therapeutics Limited announced that it has received regulatory authority approval from the Turkish Medicines and Medical Device Agency (TMMDA) to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD). As previously advised, the Company had submitted a Clinical Trial Application (CTA) for approval to conduct the Phase IIb trial in UK, Bulgaria and Turkey. This first trial approval by a regulatory authority is an important milestone for the Company in affirming the quality and acceptability of the Phase IIb trial design and critically, in providing the `green light' for trial initiation at expected high patient enrolling sites. The Phase IIb study aims to enrol and randomize 45 non-ambulant boys with DMD from multiple clinical trial sites in Europe and Australia. Following the initial six-month regimen of either placebo, 25 mg or 50 mg ATL1102 once weekly (blinded phase), participants will continue into a further six-month open label treatment period. Trial approvals in Bulgaria, the UK and Australia are expected to come through in a staggered manner depending on the respective regulatory agencies' evaluation process and timelines. The Company will make further announcements as and when material progress updates emerge. As per previous guidance, reporting of the results from the blinded phase of the trial is anticipated in First half of 2024.공시 • Feb 03Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMDAntisense Therapeutics Limited reported initial positive muscle functional data from a DMD mdx animal study assessing the use of the combination of antisense (ASO) to CD49d with a dystrophin exon skipping restoration drug. The use of the combination improved the specific maximum force of the extensor digitorum longus (EDL) muscle, a lower leg muscle, and the eccentric muscle force remaining following induced damage to the EDL. This functional data supports the potential use of ATL1102 in combination with dystrophin restoration drugs to improve therapeutic outcomes in patients with DMD. Under the collaborative research agreement with the Murdoch Children's Research Institute's (MCRI), six groups of DMD mdx mice (n=8 per group) were treated for 6 weeks with antisense oligonucleotide to CD49d (mouse equivalent of ATL1102), or control oligonucleotide mismatch or saline treatments, or the morpholino exon skipping dystrophin restoration drug alone and in combination. The muscle physiology of the EDL was assessed for force parameters including specific maximum force and the force drop following 1 to 10 eccentric (lengthening) contraction each involving induced muscle damage by the stretching of the muscle by 10%. The EDL is 1 of 4 muscles in the front of the lower leg whose function is to invert the foot at the ankle. Another of these muscles is the tibialis anterior (TA) on which the ASO to CD49d has previously reported a benefit in reducing eccentric muscle damage in mdx mice. The ASO to CD49d and morpholino exon skipping combination improved the specific maximum force (the maximum force corrected for size/mass and cross-sectional area of the EDL muscle) and both the eccentric muscle force remaining after a single and 10 repeated lengthening contractions with statistically significant effects compared to saline control. This combination after the 10 repeated lengthening contractions, also showed a significant effect (P<0.001) compared to the exon skipping drug used alone and the exon skipping drug used together with the control oligo. In addition, the ASO to CD49d showed a significant effect vs the saline and its control oligo. The morpholino exon skipping drug showed a significant effect compared to the saline control. A provisional patent application titled "Combination Compositions and Methods for Treatment of Muscular Dystrophy" is to be filed to cover the use of the ASO to CD49d and the morpholino exon skipping drug combination to seek protection of the combination of ATL1102 with the dystrophin restoration/exon skipping drugs to 2044, well beyond the patent life of the registered dystrophin restoration drugs. Notably the dystrophin restoration drugs have yet to demonstrate in controlled clinical studies a slowing of the loss of ambulation beyond use of corticosteroids, highlighting the clinical need for a more efficacious therapeutic approach.Further investigations are ongoing in the mdx mouse combination study to determine the possible mechanisms by which the combination approach is providing the observed functional benefits. Muscle RNA and protein samples have been isolated from the mdx mice quadricep muscle for analysis of the dystrophin levels in the muscle to determine if higher levels are seen with the use of the combination than with the dystrophin restoration agent alone. Cellular markers of inflammation and fibrosis including those observed in the ATL1102 DMD Phase II study, will also be assessed to elucidate the potential mechanisms that may be involved. Results from this analysis are anticipated before the end of the first quarter of current year 2023.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 PERC.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: PERC.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Percheron Therapeutics 배당 수익률 vs 시장PERC.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PERC.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (PERC.F) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PERC.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PERC.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PERC.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: PERC.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 20:18종가2026/05/22 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Percheron Therapeutics Limited는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jyoti PrakashEdison Investment Research
공시 • Mar 16Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 434,975,053 Price\Range: AUD 0.005 Security Features: Attached Options Transaction Features: Rights Offering
공시 • Aug 28Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025.
공시 • Nov 26Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing
공시 • Nov 15Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,160,916 Price\Range: AUD 0.008
공시 • Oct 23Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: AUD 0.08
공시 • Oct 18Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing
공시 • Oct 17Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023, at 14:00 AUS Eastern Standard Time. Location: Minter Ellison, Collins Arch Level 20 447 Collins Street Melbourne VIC 3000 Melbourne Australia Agenda: To receive and consider the Annual Financial Report of the Company for the year ended 30 June 2023 (2023 Annual Report), comprising the Financial Report, the Directors' Report, and the Auditor's Report; to consider Non-Binding Resolution to Adopt the 2023 Remuneration Report; to consider Re-Election of Director Dr. Charmaine Gittleson; to consider Ratification of Prior Issue of Shares to Institutional Investors; to consider Approval for issue of Options to Dr. James Garner; to consider Approval of Employee Share Option Plan; to consider Approval for issue of Options to Dr. Charmaine Gittleson; to consider Approval of change of Company name and modification of Constitution; and to consider Approval of 10% Placement Facility.
공시 • Jun 29Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UKAntisense Therapeutics Limited announced that it has received both regulatory authority and ethics committee approval to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD) in the United Kingdom (UK). Following these approvals, requisite contracts are anticipated to be finalised for initiation of trial sites, expected during third quarter current year 2023.
공시 • May 08+ 1 more updateAntisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023The Board of Directors of Antisense Therapeutics Limited announced the appointment of Dr James Garner MBBS MBA as Chief Executive Officer (CEO). Dr Garner will assume the roles as of 07 August 2023. This appointment follows the previously announced retirement, on 15 November 2022, of Mr. Mark Diamond from the roles of MD and CEO, with Mark's last working day 12 May 2023. To ensure continuity and leadership, Dr Charmaine Gittleson will assume the role of Executive Chairman, with immediate effect, until James is settled in his CEO and MD duties. James brings broad experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector. His previous responsibilities have included leading phase I-IV clinical trials, product registration, reimbursement, and business development. He possesses strong executive leadership and management skills that have seen him achieve outstanding results over a twenty-year career in the Pharmaceutical/Biotechnology industry including roles with Biogen, Progen Pharmaceuticals, Quintiles (an international clinical research organisation) and as Head of the Unit Development Office, AP R&D with Sanofi in Singapore. Most recently James has served as CEO of Kazia Therapeutics Limited.
공시 • Feb 15Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device AgencyAntisense Therapeutics Limited announced that it has received regulatory authority approval from the Turkish Medicines and Medical Device Agency (TMMDA) to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD). As previously advised, the Company had submitted a Clinical Trial Application (CTA) for approval to conduct the Phase IIb trial in UK, Bulgaria and Turkey. This first trial approval by a regulatory authority is an important milestone for the Company in affirming the quality and acceptability of the Phase IIb trial design and critically, in providing the `green light' for trial initiation at expected high patient enrolling sites. The Phase IIb study aims to enrol and randomize 45 non-ambulant boys with DMD from multiple clinical trial sites in Europe and Australia. Following the initial six-month regimen of either placebo, 25 mg or 50 mg ATL1102 once weekly (blinded phase), participants will continue into a further six-month open label treatment period. Trial approvals in Bulgaria, the UK and Australia are expected to come through in a staggered manner depending on the respective regulatory agencies' evaluation process and timelines. The Company will make further announcements as and when material progress updates emerge. As per previous guidance, reporting of the results from the blinded phase of the trial is anticipated in First half of 2024.
공시 • Feb 03Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMDAntisense Therapeutics Limited reported initial positive muscle functional data from a DMD mdx animal study assessing the use of the combination of antisense (ASO) to CD49d with a dystrophin exon skipping restoration drug. The use of the combination improved the specific maximum force of the extensor digitorum longus (EDL) muscle, a lower leg muscle, and the eccentric muscle force remaining following induced damage to the EDL. This functional data supports the potential use of ATL1102 in combination with dystrophin restoration drugs to improve therapeutic outcomes in patients with DMD. Under the collaborative research agreement with the Murdoch Children's Research Institute's (MCRI), six groups of DMD mdx mice (n=8 per group) were treated for 6 weeks with antisense oligonucleotide to CD49d (mouse equivalent of ATL1102), or control oligonucleotide mismatch or saline treatments, or the morpholino exon skipping dystrophin restoration drug alone and in combination. The muscle physiology of the EDL was assessed for force parameters including specific maximum force and the force drop following 1 to 10 eccentric (lengthening) contraction each involving induced muscle damage by the stretching of the muscle by 10%. The EDL is 1 of 4 muscles in the front of the lower leg whose function is to invert the foot at the ankle. Another of these muscles is the tibialis anterior (TA) on which the ASO to CD49d has previously reported a benefit in reducing eccentric muscle damage in mdx mice. The ASO to CD49d and morpholino exon skipping combination improved the specific maximum force (the maximum force corrected for size/mass and cross-sectional area of the EDL muscle) and both the eccentric muscle force remaining after a single and 10 repeated lengthening contractions with statistically significant effects compared to saline control. This combination after the 10 repeated lengthening contractions, also showed a significant effect (P<0.001) compared to the exon skipping drug used alone and the exon skipping drug used together with the control oligo. In addition, the ASO to CD49d showed a significant effect vs the saline and its control oligo. The morpholino exon skipping drug showed a significant effect compared to the saline control. A provisional patent application titled "Combination Compositions and Methods for Treatment of Muscular Dystrophy" is to be filed to cover the use of the ASO to CD49d and the morpholino exon skipping drug combination to seek protection of the combination of ATL1102 with the dystrophin restoration/exon skipping drugs to 2044, well beyond the patent life of the registered dystrophin restoration drugs. Notably the dystrophin restoration drugs have yet to demonstrate in controlled clinical studies a slowing of the loss of ambulation beyond use of corticosteroids, highlighting the clinical need for a more efficacious therapeutic approach.Further investigations are ongoing in the mdx mouse combination study to determine the possible mechanisms by which the combination approach is providing the observed functional benefits. Muscle RNA and protein samples have been isolated from the mdx mice quadricep muscle for analysis of the dystrophin levels in the muscle to determine if higher levels are seen with the use of the combination than with the dystrophin restoration agent alone. Cellular markers of inflammation and fibrosis including those observed in the ATL1102 DMD Phase II study, will also be assessed to elucidate the potential mechanisms that may be involved. Results from this analysis are anticipated before the end of the first quarter of current year 2023.